Clinically, high serum IL-6 levels in early systemic sclerosis-ILD predict a decline in lung function and increased mortality, suggesting that IL-6 is a biomarker of the immune-fibrotic phenotype [197]. This evidence concerns the gene IL6 and interstitial lung disease.